BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33462898)

  • 1. CD4
    Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
    Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):593-603. PubMed ID: 22252753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma.
    Kågedal Å; Hjalmarsson E; Farrajota Neves da Silva P; Piersiala K; Georén SK; Margolin G; Munck-Wikland E; Winqvist O; Häyry V; Cardell LO
    Sci Rep; 2020 Dec; 10(1):22352. PubMed ID: 33339891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves' disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69.
    Gessl A; Waldhäusl W
    Clin Immunol Immunopathol; 1998 May; 87(2):168-75. PubMed ID: 9614932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
    Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
    Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoregulatory molecules in patients with gestational diabetes mellitus.
    Pendeloski KP; Mattar R; Torloni MR; Gomes CP; Alexandre SM; Daher S
    Endocrine; 2015 Sep; 50(1):99-109. PubMed ID: 25754913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triggering of T cell-mediated immune responses by allogenic tumor cell vaccine in patients with oral cancer.
    Devarapu SK; Sharma SC; Das SN
    Immunopharmacol Immunotoxicol; 2006; 28(3):387-95. PubMed ID: 16997788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing.
    Gessl A; Waldhäusl W
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2204-9. PubMed ID: 9626161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.
    De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Rottey S; Ferdinande L
    Pathology; 2017 Jun; 49(4):397-404. PubMed ID: 28427753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and ex vivo expansion of rare in situ cytokine secreting T cell populations from tumor tissue and blood of oral squamous cell carcinoma patients.
    Stamova S; Ott-Rötzer B; Smetak H; Schäffler K; Eder R; Fink I; Hoffmann P; Reichert TE; Beckhove P; Spanier G
    J Immunol Methods; 2021 Sep; 496():113086. PubMed ID: 34146580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.